CD25, also known as the interleukin-2 receptor alpha chain (IL-2Rα). This receptor is a key marker found at high levels on the surface of certain cancer cells, most notably the malignant Reed-Sternberg cells that define classic Hodgkin lymphoma. It is also expressed on some T-cell malignancies and a subset of activated immune cells. The antibody component of Camidanlumab specifically binds to CD25 on the tumor cell surface. This binding triggers the internalization of the entire ADC into the cancer cell. Inside the cell, the linker is cleaved, releasing its pyrrolobenzodiazepine (PBD) dimer payload—a potent, DNA-interactive agent that forms irreversible cross-links in the DNA helix. This damage leads to cell cycle arrest and programmed cell death.